Patents
Literature
32 results about "Pathway analysis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In bioinformatics research, pathway analysis software is used to identify related proteins within a pathway or building pathway de novo from the proteins of interest. This is helpful when studying differential expression of a gene in a disease or analyzing any omics dataset with a large number of proteins. By examining the changes in gene expression in a pathway, its biological causes can be explored. Pathway is the term from molecular biology which depicts an artificial simplified model of a process within a cell or tissue. A typical pathway model starts with an extracellular signaling molecule that activates a specific receptor, thus triggering a chain of protein-protein or protein-small molecule interactions. Pathway analysis helps to understand or interpret omics data from the point of view of canonical prior knowledge structured in the form of pathways diagrams. It allows finding distinct cell processes (Cellular processes), diseases or signaling pathways that are statistically associated with selection of differentially expressed genes between two samples. Often but erroneously pathway analysis is used as synonym for network analysis (functional enrichment analysis and gene set analysis).
Drug effect prediction method for drug research and development
The invention discloses a drug effect prediction method for drug research and development, and relates to the technical field of drug effect analysis, and the method comprises the steps: collecting drug and target data from a plurality of data sources, and carrying out the preprocessing of the drug and target data; and carrying out feature analysis on the basis of the preprocessed drug and target data to obtain a comprehensive feature sequence, carrying out gene and pathway analysis on a disease applied by the drug, carrying out disease feature coding, and then modeling a disease background. According to the method, drug-target pairs with potential drug effects can be rapidly screened in the early stage of drug research and development through drug effect prediction, further research on a large number of invalid compounds is avoided, time and resources are saved, and then, the interaction strength between the drug and the target is predicted through the model, so that the drug effect is improved. And comprehensive analysis is carried out in combination with a disease background, so that potential drug candidate molecules can be identified more accurately, and the research and development cycle is further shortened.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE
Multi-omics deep learning based colorectal cancer liver metastasis detection method and system
The application discloses a kind of based on multi-omics deep learning colorectal cancer liver metastasis detection method and system, comprising: extracting the feature gene group with CRC transfer-metabolic dual function, and construct CRC transfer risk prediction model foundation, based on analysis CRC transfer risk probability to screen the molecular marker with CRC transfer nature and CRLM specific characteristics as initial candidate biomarker;Meanwhile, from the metabolome to obtain the differential expression metabolite corresponding to CRLM patient sample and LCRC patient sample metabolome, and the enrichment pathway analysis of transcriptome and metabolome is combined to construct CRLM multi-layer core metabolic network, for the screening core biomarker of colorectal cancer liver metastasis accurate detection in accordance with, entire method can effectively screen the biomarker for detecting colorectal cancer liver metastasis.
Owner:ZHEJIANG UNIV
Colorectal cancer liver metastasis detection method and system based on multi-omics deep learning
The invention discloses a colorectal cancer liver metastasis detection method and system based on multi-omics deep learning, and the method comprises the steps: extracting a characteristic gene group with CRC metastasis-metabolism dual functions, and on the basis of constructing a CRC metastasis risk prediction model, screening molecular markers with CRC metastasis general and CRLM specific characteristics based on the analysis of CRC metastasis risk probability, the biomarker is used as an initial candidate biomarker; meanwhile, a CRLM patient sample and differential expression metabolites corresponding to an LCRC patient sample metabolome are obtained from a metabolome, and a CRLM multilayer core metabolic network is constructed in combination with enrichment pathway analysis of a transcriptome and the metabolome, so that core biomarkers are screened for accurate detection of colorectal cancer liver metastasis; the whole method can effectively screen the biomarker beneficial to detection of colorectal cancer liver metastasis.
Owner:ZHEJIANG UNIV
A disease treatment target discovery and drug prediction method based on multi-omics network and deep learning model
This invention relates to a method for disease therapeutic target discovery and drug prediction based on multi-omics networks and deep learning models, belonging to the interdisciplinary field of bioinformatics and artificial intelligence drug discovery. The method includes: integrating genomic expression profiles and common molecular interaction data from disease and control groups to construct a candidate whole-genome network; refining the network based on expression profile data through systematic modeling and the AIC criterion to obtain the real molecular interaction network; extracting the core network using the master network projection method and identifying key targets through pathway analysis; predicting candidate drugs interacting with the targets using a pre-trained deep neural network model; and finally screening potential therapeutic drugs based on multi-dimensional criteria such as regulatory ability, sensitivity, and toxicity. This invention achieves a complete integration from disease mechanism analysis to drug prediction, and is particularly suitable for complex diseases such as atopic dermatitis. It can systematically discover precise targets and efficiently predict repositionable drugs, significantly improving R&D efficiency.
Owner:NINGBO CHSIRGA METAL PROD CO LTD
Method for analyzing angiogenesis promoting mechanism of qi-regulating and blood-activating dropping pills based on network pharmacology
The invention relates to the technical field of traditional Chinese medicine compound action mechanism research, and discloses a method for analyzing an angiogenesis promoting mechanism of a qi-regulating and blood-activating dropping pill based on network pharmacology, and the method comprises the following steps: S1, blood-entering component identification: identifying blood-entering components and metabolites of the qi-regulating and blood-activating dropping pill to obtain structure information of 18 blood-entering components and metabolites; s2, target spot prediction and screening; s3, core target point analysis; s4, network construction and analysis: constructing a drug-in-blood component-target-disease network, and determining a core in-blood component of which the degree value is greater than the average value through topological analysis; s5, function enrichment and pathway analysis: performing GO function enrichment analysis and KEGG signal pathway analysis on the target spots intersected in S2, and determining a core pathway for promoting angiogenesis; s6, carrying out molecular docking verification; and S7, in-vitro activity verification. Through integration of network pharmacology, molecular docking and in-vitro experiment verification, the action mechanism of the qi-regulating and blood-activating dropping pill for promoting angiogenesis is systematically disclosed.
Owner:CENT SOUTH UNIV
Multi-omics-based Changbai Mountain Chinese bee honey characteristic component analysis method
The invention relates to the technical field of honey identification, in particular to a multi-omics-based Changbai Mountain Chinese bee honey characteristic component analysis method. According to the method, mass spectrometric detection is carried out on the Changbai Mountain apis cerana honey and the reference substance honey, qualitative and quantitative analysis is carried out on metabolites and proteins of the honey, metabonomics and proteomics information is obtained, and metabonomics and proteomics difference information of the Changbai Mountain apis cerana honey and the reference substance honey is obtained; the method comprises the following steps: carrying out functional annotation on the Chinese bee honey, finding out KEGG pathways annotated by two groups of schools by utilizing KEGG database pathway analysis, carrying out expression correlation analysis and O2PLS analysis on the KEGG pathways annotated by the two groups of schools, and screening characteristic components of the Chinese bee honey in the Changbai Mountain; potential characteristic substances of the Changbai Mountain apis cerana honey are obtained through screening, and a scientific basis is further provided for origin traceability and quality identification of the apis cerana honey.
Owner:JILIN AGRI SCI & TECH COLLEGE
Method for analyzing target spot of cyclosporine for treating aplastic anemia
The invention relates to the technical field of bioinformatics, and provides an analysis method for treating aplastic anemia (AA) targets by cyclosporine, which comprises the following steps: collecting plasma samples from a preliminary diagnosis patient, a disease stable period patient and a healthy control group; the method comprises the following steps: based on a DIA quantitative proteomics method, analyzing proteins in a plasma sample by adopting a liquid chromatography-mass spectrometer (LC-MS) method, and screening differential expression proteins; carrying out enrichment analysis and pathway analysis on the differential expression protein; verifying the expression levels of the differential expression proteins in different groups by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method to obtain key differential expression proteins; a molecular docking technology is adopted to verify the binding capacity of cyclosporine and the differential expression protein, and the potential of the key differential expression protein as a therapeutic target is determined. Different differential proteins of AA patients and healthy people before and after treatment are successfully obtained, an experimental basis is provided for exploring a mechanism for treating AA by cyclosporine, and possibility is provided for searching a new treatment target.
Owner:YIXING PEOPLES HOSPITAL
Gene expression prediction method based on deductive learning and gene knowledge ontology
The invention discloses a gene expression prediction method based on anti-deductive learning and gene knowledge ontology, and aims to solve the problems of large data demand and poor interpretability in a traditional gene expression prediction method. And constructing a gene expression prediction model by combining anti-deductive learning and gene knowledge ontology. Obtaining gene expression data from the public database, and carrying out data preprocessing and importance feature extraction; constructing a structured knowledge graph by using the gene knowledge ontology, and generating a logic rule set through sub-graph extraction and rule mining; an anti-deductive learning framework is adopted to fuse a machine learning module and a knowledge reasoning module, and prediction accuracy and logic consistency are improved through iterative optimization; through false label correction and label-free data utilization, the performance of the model under a small sample condition is enhanced. According to the method, the accuracy and interpretability of gene expression prediction are remarkably improved, efficient support can be provided for biological experiment design, gene regulation pathway analysis and the like, and the method has a wide application prospect.
Owner:王俊童 +1
A polypeptide with methylation function at n-position of a genus amaryllidaceae alkaloid compound, and a coding gene and application thereof
The application provides a polypeptide with N-methylation function of an Amaryllidaceae alkaloid compound, a coding gene and application thereof, and belongs to the technical field of bioengineering. The polypeptide is selected from the following (a) a polypeptide consisting of an amino acid sequence shown in SEQ ID NO. 1; (b) a polypeptide consisting of an amino acid sequence shown in SEQ ID NO. 2. The application provides a new key enzyme element for Amaryllidaceae alkaloid biosynthesis pathway analysis, metabolic engineering modification and synthetic biology research, has important scientific research value and potential industrial application prospect, meanwhile, the technical scheme is complete, the application range is wide, and the stability and anti-avoidance capability of patent protection can be improved.
Owner:NORTHWESTERN POLYTECHNICAL UNIV
A comorbidity mechanism identification method and system based on complement-coagulation axis and ceRNA network
The application relates to a comorbidity mechanism identification method and system based on a complement-coagulation axis and a ceRNA network, and relates to the technical field of biomedical testing. The method comprises the following steps: integrating transcriptome expression characteristics of different diseases and performing immune pathway analysis, taking the complement-coagulation axis as a breakthrough point, identifying an inflammatory signal module shared by endometriosis and subacute cutaneous type red lupus, and further screening candidate target points with cross expression characteristics and immune regulation functions. At the regulation mechanism level, a circRNA-miRNA-mRNA ternary regulation network containing a circRNA node is constructed to obtain more complete non-coding regulation axis information; meanwhile, a plurality of algorithms are introduced to cooperatively screen and verify an independent data set, a repeatable, verifiable and expandable molecular mechanism mining process is formed, and thus the comorbidity mechanism identification analysis between diseases is realized, and technical support and path reference are provided for comorbidity mechanism research of autoimmune diseases.
Owner:FOSHAN MATERNAL & CHILD HEALTH CARE HOSPITAL
Pathway analysis apparatus, pathway analysis method, and pathway analysis program
The partial common path detection unit 12 configured to detect a common part exclusively in a portion between a start point and an end point of a path among a plurality of disease pathways representing, as a route map, an intermolecular interaction of related molecules with respect to a disease for each of a plurality of diseases related to state changes, and the common difference information provision unit 13 configured to provide information on a detected partial common path or a molecule included in the partial common path and a non-partial common path other than the partial common path or a molecule included in the non-partial common path in a state where whether the partial common path is related or the non-partial common path is related is distinguishable are provided, and a change in pathway due to the state change of the disease can be understood by providing information so that which part is common and which part is not common between a start point and an end point of a path can be understood in a relationship between a disease pathway related to a disease before state change and a disease pathway related to the disease after the state change.
Owner:FRONTEO INC
Identification and use of SHP2 conformational disruptors for cancer treatment
PendingUS20250375443A1Organic active ingredientsPeptide/protein ingredientsCancer cellPathway analysis
Compounds were identified from SHP2 Protein Conformational Array (PCA) ELISA. These compounds can disrupt SHP2 Higher Order Structure (HOS) in vitro and induce SHP2 degradation in multiple cancer cell lines. The SHP2-KRAS-ERK pathway analysis indicated that these identified compounds could induce inactivation of the active form of ERK, P-ERK. In addition, some of the compounds can induce SHP2 and / or KRAS degradation in multiple cancer cell lines. Cancer cell line testing demonstrated that these compounds identified through SHP2 HOS disruption showed dose-dependent growth inhibition. Since the SHP2-KRAS-ERK pathway plays an important role in cancer development, these compounds can be used as potential cancer treatments.
Owner:WANG XING +1
Urine exposure biomarker of p-hydroxyacetophenone and application of urine exposure biomarker in human body load monitoring
The invention discloses a urine exposure biomarker of p-hydroxyacetophenone and application of the urine exposure biomarker in human body load monitoring. On the basis of the I / II phase metabolic transformation rule of PHAC, a targeted screening list is formed, the mass spectrum fragment collection efficiency and qualitative analysis capability are enhanced, and full spectrum screening of the urine exposure biomarkers is realized by combining high-resolution mass spectrum data and a fragment ion search system; further simulating and locking potential targets through metabolic site energy, and analyzing accurate molecular structures and metabolic conversion paths of the six PHAC urine exposure biomarkers by utilizing a fragment ion spectrum intelligent matching algorithm; meanwhile, through metabolite peak area semi-quantitative analysis, a noninvasive urine sample is utilized for the first time to determine the PHAC high-sensitivity exposure biomarker capable of monitoring loads in a human body.
Owner:SOUTH CHINA INST OF ENVIRONMENTAL SCI MEP
A Metabolomics Chromatographic Peak Extraction Method Based on Secondary Mass Spectrometry Qualitative Results
This invention discloses a method for extracting metabolomics chromatographic peaks based on secondary mass spectrometry qualitative results. This method starts with secondary mass spectrometry in metabolomics, utilizing the qualitative results from the secondary mass spectrometry in a qualitative library, combined with XCMS (XML Cryptographic Message Syntax) peak extraction results to obtain more comprehensive chromatographic peak information. This invention starts with the secondary mass spectrometry characteristics that contain more mass spectrometry information and have clear chemical meanings, improving the accuracy of chromatographic peak extraction and clarifying the specific biological significance of metabolomics chromatographic peaks. This is beneficial for further discovery of metabolomics differentials, pathway analysis, and interpretation of biological significance. Figure 1 in the accompanying drawings is a flowchart of this invention.
Owner:DALIAN CHEM DATA SOLUTION TECH CO LTD
A bioinformatics-based method for analyzing common targets of the miR-106a-363 cluster
The present invention relates to the field of bioinformatics and discloses a method for analyzing the common targets of the miR-106a-363 cluster based on bioinformatics, comprising the following steps: correlation analysis between the miR-106-363 cluster and tuberculosis; target gene and pathway analysis of tuberculosis-related members in the miR-106-363 cluster; and verification of the interaction between members of the miR-106-363 cluster and key target genes in tuberculosis infection. The present invention adopts the above-mentioned method to predict the common targets of the miR-106a-363 cluster, locates the potential key targets of the miRNA cluster affecting tuberculosis immunity through literature analysis combined with the prediction results, and verifies the regulatory relationship between the bovine miR-106a-363 cluster and the target genes, revealing its potential role in tuberculosis immunity in dairy cows, and providing a new theoretical basis and research ideas for further research on tuberculosis and anti-tuberculosis gene editing breeding targets.
Owner:NORTHWEST A & F UNIV
Single-cell pathway analysis method developed based on Overlapping Group Lasso
This invention proposes a single-cell pathway analysis method based on Overlapping Group Lasso. The model's logistic form is used to regress gene expression data and cell state for each cell. A Stability Selection algorithm is employed, performing multiple sampling regressions on the data and retaining the pathways with the most stable screening frequency as the final result. The specific steps are as follows: Step 1: Mathematical expression and preprocessing of the input cell gene expression matrix, pathway data, and cell labels; Step 2: Establishing a regression model; Step 3: Solving the regression model; Step 4: Stability selection. The model selects independent variable groups at the pathway level and, based on the characteristics of Overlapping Group Lasso, decomposes the effects of overlapping genes in different genomes, effectively avoiding the influence of overlapping gene effects.
Owner:ACAD OF MATHEMATICS & SYSTEMS SCIENCE - CHINESE ACAD OF SCI
Serum biomarkers for diagnosis and disease activity assessment of takayasu arteritis and application thereof
The application provides serum biomarkers for diagnosing and evaluating the activity of aortitis and application, and relates to the field of disease activity evaluation. The serum biomarkers are serum proteins: HP and ORM1. HP and ORM1 are determined as two new serum biomarkers through comprehensive proteomics analysis; gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis are carried out using a DAVID database; a protein-protein interaction network is constructed using Metascape. A random forest model is trained using a caret package, and a nomogram is visualized using an rms package. Serum samples are obtained, and the serum levels of HP and ORM1 are determined using a commercial ELISA kit; they are significantly related to disease activity, and are involved in inflammation / immune processes in aortitis, so the markers have the potential to serve as an auxiliary tool for monitoring the activity of aortitis.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
Experimental method for verifying effect of anti-fatty liver compound
PendingCN121344139AComponent separationMicrobiological testing/measurementPathway analysisMetabolite
The invention discloses an experimental method for verifying the effect of an anti-fatty liver compound, which comprises the following steps: S1, constructing a multi-level fatty liver model: respectively constructing a human hepatocyte line fatty degeneration model, an SPF-level mouse high fat diet induced fatty liver model and a db / db gene knockout mouse spontaneous fatty liver model, inducing fatty degeneration through a culture medium containing oleic acid and palmitic acid; s2, gradient treatment of the compound: configuring the anti-fatty liver compound to be verified into four concentration gradients of 0.1 mu mol / L, 1 mu mol / L, 10 mu mol / L and 50 mu mol / L; a multi-dimensional and multi-scale effect evaluation system is formed by integrating lipid metabolism related index detection at a cellular level, serum biochemical indexes at an animal level, liver tissue pathology and protein expression analysis and differential metabolite and pathway analysis at a metabonomics level, so that the improvement effect of a compound on the phenotype of the fatty liver can be intuitively reflected, and the effect of the compound on the phenotype of the fatty liver can be further improved. And the influence on a lipid metabolism molecular mechanism can be deeply revealed.
Owner:SHANXI MEDICAL UNIV
Multi-omics data conjoint analysis and model training method and device, equipment and medium
The invention relates to the technical field of data processing, in particular to a multi-omics data conjoint analysis and model training method and device, equipment and a medium, and the method comprises the steps: constructing a graph structure based on prior biological knowledge, selecting a center feature from vertexes of the graph structure, and taking other vertexes except the center feature in the graph structure as edge features; constructing a layer network layer based on the graph structure, wherein the first layer is an edge feature with the shortest path from each center feature as a hop in the graph structure; training a preset disease mechanism model by using the training sample to obtain a trained disease mechanism model; a biological pathway transmission layer in the disease mechanism model is used for transmitting the information of the molecular characteristics of the first layer in the molecular characteristics of the sample to the direct connection characteristics in the first layer, gradually transmitting the information of the edge molecular characteristics to the central characteristics of the zero layer, and obtaining the updated central characteristics for disease analysis. According to the technical scheme, path analysis details can be explained.
Owner:THE CHINESE UNIV OF HONG KONG (SHENZHEN)
Method for analyzing potential mechanism of EGCG (epigallocatechin gallate) intervening type 2 diabetes mellitus based on network pharmacology
The invention discloses a method for analyzing potential mechanisms of EGCG (epigallocatechin gallate) intervening type 2 diabetes mellitus on the basis of network pharmacology. The molecular mechanism of the EGCG is disclosed by integrating multiple omics technologies. The method comprises the following steps: firstly, predicting an EGCG (epigallocatechin gallate) action target spot by utilizing databases such as PubChem and SwisTargetPrediction, carrying out intersection analysis on the EGCG action target spot and a type II diabetes related pathological target spot, and screening out three key genes, namely ALOX5AP, DGAT1 and PLA2G2A; bulk transcriptome sequencing and single cell transcriptome data are combined, GO / KEGG function enrichment, GSEA / GSVA pathway analysis and five algorithms are adopted to quantify glycolipid metabolism characteristics, and it is clear that key targets participate in lipid metabolism regulation and inflammation signal transduction. Furthermore, a communication network between pancreatic duct cells is analyzed through CellChat, the type of a core cell acted by EGCG is positioned, and the high-affinity interaction of the core cell is confirmed.
Owner:SOUTHWEST FORESTRY UNIVERSITY
Method for targeting interference protein translation by using circular RNA (Ribonucleic Acid)
The invention relates to the field of molecular biology, in particular to a method for targeting interference protein translation by circular RNA (circRNA). According to the invention, translation inhibition of a target gene is realized by constructing and recombining circRNA based on a circRNA mRNA brake model. The recombinant circRNA has an internal ribosome entry site (IRES) and a reverse complementary sequence of a target gene mRNA at the same time, ribosome and the target gene mRNA can be combined in cells at the same time, and a brake is similar to the movement of mRNA on the ribosome, so that translation inhibition of the target gene is caused. The technology provided by the invention is expected to be applied to the fields of functionalization, drug target screening, cell signal transduction pathway analysis, disease treatment and the like, and realizes an inhibition effect on translation of a plurality of target proteins.
Owner:THE FIRST AFFILIATED HOSPITAL OF NAVAL MEDICAL UNIVERSITY OF CHINESE PEOPLES LIBERATION ARMY
Pathway analysis apparatus, pathway analysis method, and pathway analysis program
The partial common path detection unit 12 configured to detect a common part exclusively in a portion between a start point and an end point of a path among a plurality of disease pathways representing, as a route map, an intermolecular interaction of related molecules with respect to a disease for each of a plurality of diseases related to state changes, and the common difference information provision unit 13 configured to provide information on a detected partial common path or a molecule included in the partial common path and a non-partial common path other than the partial common path or a molecule included in the non-partial common path in a state where whether the partial common path is related or the non-partial common path is related is distinguishable are provided, and a change in pathway due to the state change of the disease can be understood by providing information so that which part is common and which part is not common between a start point and an end point of a path can be understood in a relationship between a disease pathway related to a disease before state change and a disease pathway related to the disease after the state change.
Owner:FRONTEO INC
Use of astragalol in the preparation of a product for treating or alleviating parkinson's disease
The application discloses application of astragalol in preparation of products for treating or relieving Parkinson's disease. The application explores behavioral and pathological pharmacological effects of astragalol on PD through in-vitro and in-vivo PD models, evaluates intervention effects of the astragalol on inflammation levels, and analyzes differential metabolites and genes through metabolomics and transcriptomics. Enrichment pathway analysis is used to identify intervention signal channels and key genes, and results of the metabolomics analysis are verified. Finally, the molecular mechanism of the astragalol in playing a neuroprotective role on neural inflammation and PD is clarified, and a theoretical basis is provided for development of the astragalol as a new dietary supplement.
Owner:SHANXI UNIV OF CHINESE MEDICINE
PRAK signaling pathway analysis method and system
The application relates to the technical field of data processing, and discloses a PRAK signal pathway analysis method and system. The method comprises the following steps: collecting circRNA expression profiles, miRNA regulation data and PRAK pathway protein phosphorylation data by high-throughput sequencing technology to form a comprehensive data set, mining molecular interaction relationships to construct a pathway connection matrix containing three regulation axes of P38-PRAK-HSP27, VEGFA-PRAK and PRAK-GTPBP4-RhoA, predicting the PRAK pathway activation strength value by using a graph neural network algorithm, extracting the response characteristic markers of a chemotherapy-resistant type, an apoptosis-sensitive type and a proliferation regulation type, and matching an optimal PRAK pathway intervention target point combination. The application solves the technical problem that the existing PRAK signal pathway analysis method cannot intelligently process multi-omics data and accurately predict the pathway activity state.
Owner:TIANJIN TUMOR HOSPITAL
PRAK signal path analysis method and system
The invention relates to the technical field of data processing, and discloses a PRAK signal path analysis method and system. The method comprises the steps that a circRNA expression profile, miRNA regulation and control data and PRAK pathway protein phosphorylation data are collected through a high-throughput sequencing technology to form a comprehensive data set, the molecular interaction relation is mined to construct a pathway connection matrix containing three regulation and control axes of P38-PRAK-HSP27, VEGFA-PRAK and PRAK-GTPBP4-RhoA, the PRAK pathway activation intensity value is predicted through a graph neural network algorithm, and the PRAK pathway activation intensity value is calculated. Chemotherapy drug resistance type, apoptosis sensitive type and proliferation regulation type response feature identifiers are extracted, and the optimal PRAK pathway intervention target combination is matched. The technical problem that an existing PRAK signal channel analysis method cannot intelligently process multi-omics data and cannot accurately predict the active state of the channel is solved.
Owner:TIANJIN TUMOR HOSPITAL
A SNP mutation site associated with melanization in turbot, molecular marker and its application
ActiveCN119307623BMicrobiological testing/measurementClimate change adaptationPathway analysisGermplasm
The present invention provides a SNP mutation site, molecular marker and application associated with the melanization of turbot, belonging to the field of molecular marker technology. The present invention finds a SNP site associated with the melanization of turbot through pathway analysis, SNP site screening, SNP site typing, and SNP site screening associated with the melanization of the eyeless side of turbot. The SNP site is located on the gene tyrosinase‑related protein 1b, and the base G at the 835bp position is mutated to A, which can change aspartic acid to asparagine, resulting in the eyeless side of turbot being less likely to melanize. When breeding turbot, the SNP site associated with the melanization of the eyeless side of turbot of the present invention can be used to perform pre-breeding molecular screening of turbot, thereby reducing the incidence of melanization of the eyeless side of turbot offspring from the germplasm and reducing the melanization phenomenon during turbot breeding.
Owner:SHANGHAI OCEAN UNIV
A method and system for analyzing components of a kidney-tonifying and essence-nourishing compound
This invention relates to the field of traditional Chinese medicine component analysis technology, and discloses a method and system for component analysis of kidney-tonifying and essence-nourishing compounds. The method includes physically disrupting the sample and performing multi-solvent gradient extraction to generate a multidimensional digital fingerprint; based on this, a dynamic component network model is constructed with characteristic peaks as nodes and inter-peak correlation strength and activity synergy as edges; pharmacological prior knowledge rules are injected into the model, and by calculating structure-activity relationships and metabolic pathway correlations, core functional component clusters, potential auxiliary component clusters, and inter-cluster regulatory pathways are identified; based on the identification results, targeted experiments are designed for verification and model optimization, generating a structured report. This method transforms a discrete list of components into a systematic component association network and automatically realizes functional cluster identification and pathway analysis, achieving an upgrade from component identification to systematic efficacy analysis capabilities.
Owner:HANGZHOU NUPTEC RISING BIOPRODUCTS INC LTD +1
Application of traditional Chinese medicine compound Shenhua tablet in treating diabetic nephropathy and research method of action mechanism of treating diabetic nephropathy
The invention discloses application of a traditional Chinese medicine compound Shenhua tablet in treatment of diabetic nephropathy and a research method of an action mechanism of the traditional Chinese medicine compound Shenhua tablet in treatment of diabetic nephropathy. The research method comprises the following steps: screening active ingredients and action targets of the Shenhua tablet; obtaining related targets of the diabetic nephropathy from the target library; screening a drug-disease intersection target spot; drawing a protein-protein interaction network; performing gene ontology function enrichment analysis and Beijing gene and genome encyclopedia pathway analysis; carrying out molecular docking simulation and visual analysis; performing grouping intervention on the experimental animals; and carrying out kidney tissue pathological evaluation, real-time fluorescent quantitative PCR detection, western blot analysis and immunofluorescence microscopic imaging. The core active ingredients and the main action mechanism of the Shenhua tablet for treating diabetic nephropathy are systematically researched for the first time, an experimental basis and an innovative view angle are provided for clinical application and targeted therapy of the Shenhua tablet, and meanwhile, a theoretical basis is laid for treating the disease by combining traditional Chinese medicine and western medicine.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL
Urinary biomarkers of p-hydroxyacetophenone exposure and their application in human load monitoring
This invention discloses urinary biomarkers for p-hydroxyacetophenone (PHAC) exposure and their application in human load monitoring. Based on the phase I / II metabolic transformation patterns of PHAC, this invention establishes a targeted screening list, enhances mass spectrometry fragment acquisition efficiency and qualitative analysis capabilities, and combines high-resolution mass spectrometry data with a fragment ion search system to achieve full-spectrum screening of urinary exposure biomarkers. Furthermore, it identifies potential targets through metabolic site energy simulation and utilizes a fragment ion mapping intelligent matching algorithm to achieve precise molecular structure and metabolic transformation pathway analysis of six PHAC urinary exposure biomarkers. Simultaneously, through semi-quantitative analysis of metabolite peak areas, it establishes, for the first time using non-invasive urine samples, highly sensitive PHAC exposure biomarkers suitable for human load monitoring.
Owner:SOUTH CHINA INST OF ENVIRONMENTAL SCI MEP
Method for analyzing and evaluating drug regulation metabolic pathway based on blood metabonomics
The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to a method for analyzing and evaluating a drug regulation metabolic pathway based on blood metabonomics, which comprises the following steps: constructing a model animal, and taking part of the model animal for administration treatment; collecting blood of the normal animal, the model animal and the administration animal, and detecting and analyzing metabolites in the blood; detecting and analyzing the extracted metabolites, comparing the metabolites in the blood of the normal animal and the model animal, and screening out the blood biomarker of the model animal; comparing the blood biomarker of the model animal with metabolites in the blood of the administration animal, and screening out the blood biomarker of the administration animal; and performing pathway analysis on the blood biomarker of the drug-administered animal to obtain drug-regulated metabolic pathway data. According to the method, blood markers and metabolic pathways are used as parameters, a pharmacodynamic mechanism research normal form based on diabetes blood metabolism is constructed, and the problems that an existing method is long in pharmacodynamic evaluation period and low in efficiency are solved.
Owner:MUDANJIANG NORMAL UNIV